Relmada Therapeutics Secures Exclusive License for NDV-01

The latest update is out from Relmada Therapeutics ( (RLMD) ).

On March 24, 2025, Relmada Therapeutics entered into an exclusive license agreement with Trigone Pharma for NDV-01, a novel sustained-release formulation of gemcitabine and docetaxel for treating Non-Muscle Invasive Bladder Cancer. This agreement grants Relmada worldwide rights, excluding India, Israel, and South Africa, and involves a $3.5 million upfront payment, potential milestone payments up to $200 million, and a 3% royalty on net sales. NDV-01 is expected to be a first-line therapy for NMIBC, offering significant clinical benefits, and its Phase 2 data will be presented at the American Urological Association meeting in April 2025.

More about Relmada Therapeutics

Relmada Therapeutics is a clinical-stage biotechnology company focused on developing innovative breakthrough therapies. The company’s lead investigational program, NDV-01, targets High-Grade Non-Muscle Invasive Bladder Cancer and is currently being evaluated in a Phase 2 study.

YTD Price Performance: -28.89%

Average Trading Volume: 1,122,085

Technical Sentiment Signal: Buy

Current Market Cap: $9.67M

See more insights into RLMD stock on TipRanks’ Stock Analysis page.